Primary Endpoint Results with the Second-Generation Cephea Transseptal TMVR System in Complex Mitral Valve Disease

Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients:

• Consultant Fee/Honoraria/Speaker's Bureau - Edwards Lifesciences; Abbott; Boston Scientific Corporation
• Equity/Stock(s)/Options - DASI Simulations; Opus